The effect of transforming growth factor & (TGF-&) on the expression of mRNA for the parathyroid hormone receptor and binding of iodinated parathyroid hormone-related protein in ROS 17/2.8 osteosarcoma cells was evaluated. TGF-8, stimulated a 2-7-fold increase in steady state mRNA levels for the parathyroid hormone receptor at a maximal dose of 5 ngfml, with increased levels of expression at 6 h of TGF-&-incubation, and peak levels at 8-24 h. Receptor binding studies revealed a significant increase in PTHrP-specific binding with TGF-& doses as low as 0.5 ng/ml and a 55% increase in numbers of receptors with no alteration in binding affinity with 5.0 ngfml TGF-PI. Time course studies indicated that receptor birding was increased at 24 h with peak levels reached at 48 h of treatment. PTH-stimulated CAMP levels were significantly increased in ROS 17/2.8 cells treated with TGF-fir (0.5 ng/ml) for 48 h. These data indicate that TGF-P, upregulates steady-state mRNA, ligand binding and PTH/PTHrP receptor signaling in rat osteosarcoma cells. The effects of TGF-@, on bone may be attributed in part to regulation of the PTHfPTHrP receptor at the molecular level.
introduction
Parath~oid hormone (PTH) and paratbyroid hormone-related protein (PTI-IrP) exert their effects on bone by binding to the same cell membrane receptor on osteoblasts (Jiippner et al., 1988; Nissenson et al., 1988) . The cDNA for the PTH/PTHrP receptor has recently been cloned and sequenced and belongs to the family of G protein-coupled receptors with seven transmembrane domains (Jiippner et al., 1991) . PTH and PTHrP bind to the ~/PTHrP receptor with similar affinity resulting in intracellular accumulation of CAMP and inositol trisphosphate and increased levels of intra-cellular calcium (Abou-Samra et al., 1992; Jiippner et al., 1991) . Characterization of the binding affinity and numbers of receptors per cell on osteoblasts has been extensively investigated and reviewed (Pun et al., 1990; Orloff et al., 1989) . Information regarding local and systemic regulation of the PTH/PTHrP receptor is not well known. Transfo~ing growth factor-/3 (TGF-j3) is a polypeptide growth factor localized in high concentrations in bone (Pfeilschifter et al., 1990) . It has been found to regulate several osteoblast phenotype characteristics including alkaline phosphatase activity, collagen synthesis, osteopontin and osteocalcin levels (Centrella et al., 1988) . PTH opposes the effects of TGF-j? on mitosis, collagen production, and alkaline phosphatase activity in rat calvarial cells (Centrella et al., 1988) ; however, little is known regarding the ability of TGF-P to modulate PTH or PTHrP effects. TGF-/3,
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IQ1 has been reported to stimulate production of PTHrP from uterine cells, keratinocytes, and squamous cancer cells (Casey et al., 1992; Merryman et al., 1993; Allinson and Drucker, 1992; Kiriyama et al., 1993) and to accentuate the PTH-stimulated CAMP response in UMR 106 osteoblastic cells (Gutierrez et al., 1990) . These findings suggest that TGF-#3 plays a key role in the functions of PTH/~HrP in bone; however, the ability of TGF-@ to alter expression of mRNA for the PTH/PTHrP cell surface receptor on osteoblasts is not known. The purpose of this study was to determine if TGF-P, alters PTH/PTHrP receptor mRNA levels and subsequently receptor binding and signaling in ROS 17/2.8 osteosarcoma cells.
Materials and methods
2.1. Ceil culture ROS 17/2.8 osteosarcoma cells (Majeska et al., 1980) were maintained in DMEM-F12 media containing 5% fetal bovine serum in a humidified, 5% CO,, 37°C incubator. Cell culture media and supplements were obtained from Gibco (Grand Island, NY).
Nor~~e~ blot analysis
ROS 17/2.8 cells were grown 24-48 h post-confluence prior to placement of TGF-& (recombinant human, R & D Systems, Minneapolis, MN) or vehicle control in serum-free DMEM-F12 media for designated time periods. Total RNA was isolated from one 75 cm* flask per treatment by the guanidinium isothiocyanate method (Chomczynski and Sacchi, 1987) and quantitated by A,,. Total RNA (20 pg) was denatured and electrophore~d in sample buffer (50% formamide, 10% MOPS buffer, 18% formaldehyde, 10% glycerol, 0.5% bromophenol blue, 1 pg ethidium bromide) on 1.2% agarose-formaldehyde gels (60 V, 4.5 h). The RNA was transferred to nylon membranes (Duralon U.V., Stratagene, La Jolla, CA) via passive transfer, and crosslinked by U.V. transillumination (Stratalinker, Stratagene Inc.). The nylon membranes were pre-hybridized for 1 h at 42°C (53% formamide, 5 X SSC, 100 mM Tris, 10 x Denhardt's, 0.2% SDS and 1 mg/ml denatured salmon sperm DNA) in a hybridization oven. The rat PTH/PTHrP receptor cDNA probe (RISE)) (Abou-Samra et al., 1992) was prepared from a 1810 bp coding region cDNA fragment subcloned into pcDNA I (Invitrogen, San Diego, CA) and was labeled with [cw32P]dCTP (NEN DuPont, Boston, MA) using a random primer labeling kit (Stratagene) to lo9 dpm/pg. The probe was added to the pre-hybridization tube with the membrane and hybridized overnight at 42°C. The membranes were washed 8 times for 15 min each wash at 50°C with decreasing concentrations of SSC (2 x -0.25 x ) in 0.1% SDS. The blots were exposed to Kodak X-OMAT film at -70°C with intensifying screens, and developed in an automatic film processor. Blots were also stripped and reprobed with a cDNA probe for 185 rRNA (de Papp and Stewart, 1993) as a control for even loading.
Binding assays
PTH/PTHrP receptor binding assays were performed as described (McCauley et al., 1992a) . Briefly, ROS 17/2.8 cells, grown to confluence in 24-well plates, were pretreated with TGF-& or control vehicle in DMEM-F12 media containing l-2% fetal bovine serum for 48 h. For binding assays triplicate wells were incubated with 250~-350~ cpm of monoiodinated ['2511PTHrP (l-36) (McCauley et al., 1992b) in addition to varying concentrations of nonradioactive PTHrP (l-36) (Bachem, Torrance, CA). The cells were incubated for 2 h at 4°C with gentle shaking. The unbound peptides were washed off the cell monolayer twice with Hank's buffered salt solution (HBSS), the cells were lysed with 0.5 M NaOH for 30 min, and the resultant suspension counted in a scintillation counter. Specific binding was calculated by subtracting the radioactivity bound in the presence of excess unlabeled PTHrP (l-36) (1.0 FM) from that observed in the presence of tracer only and expressed as a ratio of the total cpm added.
Adenylate cyclase stimulation assay
The adenylate cyclase stimulation assay and CAMP binding assay were performed as previously described (McCauley et al., 1992b) . Briefly, ROS 17/2.8 cells were grown 24-48 h postcon~uence in 24-well plates. TGF-& or vehicle control was preincubated with confluent ROS cells in triplicate for 48 h with a media change at 24 h. The cells were rinsed and incubated with bPTH (l-34) (Bachem) (10 nM) or control vehicle for 10 min at 37°C in calcium-and magnesium-free HBSS containing 0.1% bovine serum albumin (BSA) and 1 mM isobutylmethylxanthine (IBMX). The media was aspirated and 250 ~1 ice-cold 5% perchloric acid was added to each well. The plates were incubated at -20°C overnight to extract the CAMP. After thawing, the extract was transferred to tubes, the pH was adjusted to 7.5 with 4 N KOH, and the extract was centrifuged to remove the precipitate. The neutralized extract was then assayed for CAMP content using a CAMP binding protein assay. Parallel wells were analyzed for cell number by trypan blue dye enumeration.
The CAMP binding protein assay was performed as follows. To each tube was added assay buffer (50 mM Tris, 5 mM EDTA, pH 7.4) 100 ~1 standards or un-knowns, E3H]cAMP (10000 cpm/tube), and CAMP binding protein sufficient to bind 40-60% of the radioactivity in a final volume of 250 ~1. The tubes were incubated for 90 min on ice. Dextran-coated charcoal (0.5 mg/ml d xt e ran and 5.0 mg/ml charcoal) was added to each tube (600 ~0, incubated an additional 30 min on ice, then centrifuged to remove the unbound from the bound ALP-binding protein-[ 3H]cAMP complexes. The supernatant was decanted directly into scintillation vials and counted in a liquid scintillation spectrophotometer.
Samples were run in duplicate and the concentration of CAMP was calculated by the ioglogit method using Securia 1.0 (Packard Instruments, Indianapolis, IN). Data were expressed as pmol cAMP/103 cells.
Statistical analysh
Data for the % specific binding and adenylate cyclase assays were evaluated using Instat 1.1 (Graph-PAD Software, San Diego, CA) and an MS/DOS computer. Analysis of variance followed by multiple comparisons using a Tukey's mean separation test were used to determine statistically significant (p < 0.05) differences between groups. Scatchard analysis of the binding curve for PTHrP was performed with LIG-AND, a nonlinear curve fitting software program (Munson and Robard, 1980) . Autoradiographs from the northern blot analysis were evaluated for relative There was an increase in mRNA expression up to 5.0 ng/mi, and a reduction in expression at 10 ng/ml. signal density with NIH Image Software on a Macintosh computer.
Results

Northern blot analysis
Northern blot analysis revealed a 3-7-fold increase in expression of mRNA for the PTH/PTHrP receptor when ROS cells were treated with TGF-P, (5.0 ng/ml) for 12 h (Fig. 1) . TGF-j3, stimulated a dose-dependent increase in mRNA expression up to 5.0 ng/ml, with a diminution of message expression at 10 ng/ml (Fig. 2) . Time dependence studies revealed a two-fold increase in PTH/~HrP receptor mRNA expression after 6 h of TGF-& (5.0 ng/ml) treatment and up to three-fold increases in mRNA expression at 24 h of treatment (Fig. 3) K, values and number of receptors/cell were calculated from data in Fig. 6 by Scatchard analysis.
a loss of the TGF-/3,-upregulation of PTH/PTHrP receptor mRNA levels (Fig. 4) . This indicates that TGF-/3, is dependent on protein synthesis to mediate its effects on the PTH/PTHrP receptor.
Binding assays
TGF-/3, stimulated an increase in specific binding of iodinated PTHrP to ROS 17/2.8 cells which was statistically significant with doses as low as 0.5 ng/ml TGF-& (48 h pre-treatment) (Fig. 5) . The treatments were routinely placed in cell culture media containing low levels of fetal bovine serum since higher serum levels stimulated PTH/PTHrP receptor levels and masked the TGF-/I, effects (data not shown). Evaluation of PTHrP competitive binding (Fig. 6) by Scatchard analysis indicated that the binding affinity of PTHrP was similar for TGF-&-treated (5.0 ng/ml) and control cells (Table 1 ) and similar to that reported by other investigators for osteoblastic cells (Nissenson et al., 1988; Abou-Samra et al., 1989) . Calculation of the number of receptors per cell revealed that there was an There was no significant difference in control levels of CAMP (no PTH-stimulation) with TGF-/?, pre-incubation; however, with PTH-stimulation, CAMP levels were greater (p < 0.05) with 0.5 ng/ml and 1.0 ng/ml vs. 0 ng/ml TGF-j3,.
increase of approximately 55% in numbers of receptors when the ROS cells were pre-incubated with TGF-P, for 48 h. The cell number as determined by trypan blue dye exclusion in treatment and control groups was not different (data not shown). There was a significant increase in percent specific binding after 24 h of TGF-P-treatment (5.0 ng/ml) which increased up to 48 h; and remained increased at 72 h (Fig. 7) .
Adenyla te cyclase stimulation assay
The ability of TGF-Pi to alter PTH-stimulated adenylate cyclase activity was evaluated in confluent ROS cells pre-incubated with TGF-P, (0, 0.1, 0.5, 1.0 ng/ml) followed by a 10 min PTH stimulation (10 nM). There was no difference in the basal levels of CAMP in cells pre-incubated with TGF-P,; however, significantly greater levels of CAMP were found in response to PTH-stimulation in the 0.5 and 1.0 ng/ml TGF-Pi-pretreated cells (Fig. 8) .
Discussion
The present study provides the first evidence for upregulation of the PTH/PTHrP receptor by TGF-Pi at the level of mRNA expression in osteoblastic cells. Previous reports have indicated that TGF-P enhanced PTH stimulation of adenylate cyclase in osteoblastic cells (ROS 17/2.8 and UMR-106) and TGF-& inhibited adenylate cyclase and PTHrP binding in renal (OK) cells (Gutierrez et al., 1990; Schneider et al., 1992; Seitz et al., 1992; Law et al., 1993) . Gutierrez et al. (1990) suggested that TGF-/3 did not alter PTH receptor affinity which is in agreement with our findings; however they also suggested that the modulatory effect of TGF-P was localized to nonreceptor components of the adenylate cyclase system. We found that PTH-stimulated CAMP levels, PTHrP receptor binding and PTH/PTHrP receptor mRNA upregulation were significantly elevated with similar levels of TGF-P, in ROS cells. This indicates that TGF-Pi acts directly to increase PTH/PTHrP receptor numbers on osteoblastic cells by increasing the steady state PTH/PTHrP receptor mRNA levels. This is in support of findings by Schneider et al. (1992) which found an increase in PTH/PTHrP receptors and the G protein stimulatory subunit with TGF-P-treatment of UMR-106 osteoblastic cells.
TGF-/3 upregulates the binding of PTH on chondrocytes and osteoblastic cells, both of which require 24-48 h of incubation with TGF-/3 (Takigawa et al., 1991; Schneider et al., 1992) . This is in agreement with our studies since specific binding increased over a 48 h period. Our study indicates that mRNA levels are increased in response to TGF-Pi as early as 6 h, which is indicative of a rapid effect of TGF-/3, on ROS cells; the resultant increase in the receptor determined by ligand binding reached a peak at 48 h.
The results of this study indicate that the upregulation of the PTH/PTHrP receptor mRNA is rapid; however, it is dependent on the synthesis of another protein(s) since cycloheximide inhibited the TGP-Pi-induced upregulation of PTH/PTHrP receptor mRNA. Alternately, the cycloheximide may have effected an increase in the transcription of a gene whose product inhibited PTH/PTHrP receptor gene transcription. TGF-P has been reported to have a wide variety of effects on osteoblastic cells dependent on the state of differentiation of the cell. Clonal populations of rat osteoblastic cells exposed to TGF-P, respond differently to PTH stimulation based on the differentiation state. Mature osteoblastic cells have increased PTHstimulated CAMP levels in response to TGF-&; whereas osteoblast precursors do not have altered PTH responses with TGF-/?, treatment (Yamaguchi et al., 1991) . Furthermore, preliminary data indicate that primary rat calvarial cells respond to TGF-& with a decrease in PTH responsiveness (Jongen et al., 1993) . Inconsistencies in TGF-P actions on osteoblasts in vitro suggest that the stage of differentiation, dose, and culture conditions may alter TGF-P effects. The results from our study are consistent with the ROS 17/2.8 cells representing a mature osteoblastic cell type that responds to TGF-/?, with increased numbers of PTH/PTHrP receptors. Other phenotypic characteristics of a differentiated osteoblastic cell that have been reported to be stimulated by TGF+, in ROS 17/2.8 cells include alkaline phosphatase activity, osteopontin, and type I collagen (Centrella et al., 1988; Pfeilschifter et al., 1990; Noda and Rodan, 1987) . Since TGF-& is present in large amounts in the extracellular matrix of bone, and is released and activated during bone resorption, it has been thought to be an important factor in the process of coupling of bone resorption and bone formation (Pfeilschifter et al., 1990) . The results from this study indicate that TGF-/3, may exert its effects on the bone remodeling cycle at least in part by its ability to regulate PTH/PTHrP receptor mRNA, its translation product, and signaling pathway.
Acknowledgments
Support for these studies was provided in part by The University of Michigan Geriatric Research and Training Center, The University of Michigan Comprehensive Cancer Center's Institutional Grant from The American Cancer Society, and The American Federation for Aging Research.
